235 related articles for article (PubMed ID: 28767702)
1. Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network.
Liu X; Wang W; Song G; Wei X; Zeng Y; Han P; Wang D; Shao M; Wu J; Sun H; Xiong G; Li S
PLoS One; 2017; 12(8):e0182558. PubMed ID: 28767702
[TBL] [Abstract][Full Text] [Related]
2. NR4A1 Promotes Diabetic Nephropathy by Activating Mff-Mediated Mitochondrial Fission and Suppressing Parkin-Mediated Mitophagy.
Sheng J; Li H; Dai Q; Lu C; Xu M; Zhang J; Feng J
Cell Physiol Biochem; 2018; 48(4):1675-1693. PubMed ID: 30077998
[TBL] [Abstract][Full Text] [Related]
3. Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice.
Song G; Han P; Sun H; Shao M; Yu X; Wang W; Wang D; Yi W; Ge N; Li S; Yi T
J Int Med Res; 2018 Jul; 46(7):2883-2897. PubMed ID: 29896981
[TBL] [Abstract][Full Text] [Related]
4. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.
Wang ZS; Xiong F; Xie XH; Chen D; Pan JH; Cheng L
BMC Nephrol; 2015 Mar; 16():44. PubMed ID: 25886386
[TBL] [Abstract][Full Text] [Related]
5. Huangqi-Danshen decoction alleviates diabetic nephropathy in
Liu X; Lu J; Liu S; Huang D; Chen M; Xiong G; Li S
Am J Transl Res; 2020; 12(3):989-998. PubMed ID: 32269729
[TBL] [Abstract][Full Text] [Related]
6. Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy.
Xing L; Fang J; Zhu B; Wang L; Chen J; Wang Y; Huang J; Wang H; Yao X
Life Sci; 2021 Mar; 269():119068. PubMed ID: 33476631
[TBL] [Abstract][Full Text] [Related]
7. Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats.
Chen J; Chen Y; Luo Y; Gui D; Huang J; He D
Eur J Pharmacol; 2014 Aug; 736():86-94. PubMed ID: 24809932
[TBL] [Abstract][Full Text] [Related]
8. Astragaloside IV ameliorates diabetic nephropathy in
Feng H; Zhu X; Tang Y; Fu S; Kong B; Liu X
Int J Mol Med; 2021 Aug; 48(2):. PubMed ID: 34278447
[TBL] [Abstract][Full Text] [Related]
9. Astragaloside IV protects against diabetic nephropathy via activating eNOS in streptozotocin diabetes-induced rats.
Fan Y; Fan H; Zhu B; Zhou Y; Liu Q; Li P
BMC Complement Altern Med; 2019 Dec; 19(1):355. PubMed ID: 31805910
[TBL] [Abstract][Full Text] [Related]
10. Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy.
Guo H; Wang Y; Zhang X; Zang Y; Zhang Y; Wang L; Wang H; Wang Y; Cao A; Peng W
Sci Rep; 2017 Jul; 7(1):6852. PubMed ID: 28761152
[TBL] [Abstract][Full Text] [Related]
11. Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression.
Gui D; Huang J; Guo Y; Chen J; Chen Y; Xiao W; Liu X; Wang N
Cytokine; 2013 Mar; 61(3):970-7. PubMed ID: 23434274
[TBL] [Abstract][Full Text] [Related]
12. Klotho ameliorates diabetic nephropathy via LKB1-AMPK-PGC1α-mediated renal mitochondrial protection.
Lee J; Tsogbadrakh B; Yang S; Ryu H; Kang E; Kang M; Kang HG; Ahn C; Oh KH
Biochem Biophys Res Commun; 2021 Jan; 534():1040-1046. PubMed ID: 33121684
[TBL] [Abstract][Full Text] [Related]
13. Effects of Astragaloside IV on diabetic nephropathy in rats.
Lu WS; Li S; Guo WW; Chen LL; Li YS
Genet Mol Res; 2015 May; 14(2):5427-34. PubMed ID: 26125738
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of astragaloside IV on db/db mice with diabetic retinopathy.
Ding Y; Yuan S; Liu X; Mao P; Zhao C; Huang Q; Zhang R; Fang Y; Song Q; Yuan D; Xie P; Liu Y; Liu Q
PLoS One; 2014; 9(11):e112207. PubMed ID: 25411784
[TBL] [Abstract][Full Text] [Related]
15. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
[TBL] [Abstract][Full Text] [Related]
16. Astragaloside IV/lncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats.
Lei X; Zhang L; Li Z; Ren J
Drug Des Devel Ther; 2018; 12():2785-2793. PubMed ID: 30233141
[TBL] [Abstract][Full Text] [Related]
17. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice.
Sugaru E; Nakagawa T; Ono-Kishino M; Nagamine J; Tokunaga T; Kitoh M; Hume WE; Nagata R; Taiji M
Am J Physiol Renal Physiol; 2006 Apr; 290(4):F813-20. PubMed ID: 16278277
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes.
Sedeek M; Gutsol A; Montezano AC; Burger D; Nguyen Dinh Cat A; Kennedy CR; Burns KD; Cooper ME; Jandeleit-Dahm K; Page P; Szyndralewiez C; Heitz F; Hebert RL; Touyz RM
Clin Sci (Lond); 2013 Feb; 124(3):191-202. PubMed ID: 22920224
[TBL] [Abstract][Full Text] [Related]
19. Thyroid hormone ameliorates diabetic nephropathy in a mouse model of type II diabetes.
Lin Y; Sun Z
J Endocrinol; 2011 May; 209(2):185-91. PubMed ID: 21307121
[TBL] [Abstract][Full Text] [Related]
20. The antioxidant peptide SS31 prevents oxidative stress, downregulates CD36 and improves renal function in diabetic nephropathy.
Hou Y; Shi Y; Han B; Liu X; Qiao X; Qi Y; Wang L
Nephrol Dial Transplant; 2018 Nov; 33(11):1908-1918. PubMed ID: 30388276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
